Page last updated: 2024-12-08
sintropium
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 174170 |
| CHEMBL ID | 2111077 |
| MeSH ID | M0134982 |
Synonyms (10)
| Synonym |
|---|
| sintropium |
| sintropium ion |
| 8-azoniabicyclo(3.2.1)octane, 8-methyl-8-(1-methylethyl)-3-((1-oxo-2-propylpentyl)oxy)-, (3-endo,8-syn)- |
| 768313-41-3 |
| 3n9b1pl5qg , |
| unii-3n9b1pl5qg |
| sintropium cation |
| CHEMBL2111077 |
| Q27257743 |
| [(1s,5r)-8-methyl-8-propan-2-yl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate |
Research Excerpts
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Sintropium bromide has a prompt anticholinergic action and for this reason may be used in the treatment of painful conditions of the bile, gastro-enteric and renal tracts, and also during the course of endoscopic examinations." | ( [The use of syntropium bromide as an antispasmodic]. Benazzi, E; Bossi, M; Cacioli, D; Galeone, M; Moise, G; Monti, G, 1985) | 0.99 |
| "Sintropium bromide has a prompt anticholinergic action and for this reason may be used in the treatment of painful conditions of the bile, gastro-enteric and renal tracts, and also during the course of endoscopic examinations." | ( [The use of syntropium bromide as an antispasmodic]. Benazzi, E; Bossi, M; Cacioli, D; Galeone, M; Moise, G; Monti, G, 1985) | 0.99 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (3)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (57.14%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (42.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||